Blueprint: Brain-heart Interaction in Coronary Plaque Stability and Cardiovascular Events

Sponsor
Shanghai Zhongshan Hospital (Other)
Overall Status
Recruiting
CT.gov ID
NCT05545618
Collaborator
(none)
300
4
95.9
75
0.8

Study Details

Study Description

Brief Summary

The effect of brain-heart interaction remains unclear. The study aims to investigate the biological interconnection between brain neural activity and coronary plaque morphological and inflammatory features, as well as their connection with clinical outcomes.

Condition or Disease Intervention/Treatment Phase
  • Diagnostic Test: CCTA and 18F-FDG-PET/CT

Detailed Description

Brain neural activity assessed by resting amygdalar activity (AmygA) can predict cardiovascular events. However, its biological interconnection with plaque vulnerability i is not fully understood. Coronary computed tomographic angiography (CCTA) is a non-invasive technique that enables comprehensive assessment of morphological characteristics of coronary atheroma and estimates the level of plaque instability. Recently, perivascular fat attenuation index (FAI) enables assessment of coronary inflammation by analyzing changes of perivascular adipose tissue attenuation in CCTA.

18F-fluorodeoxyglucose-positron emission tomography/computed tomography (18F-FDG-PET/CT) enables simultaneous estimation of multi-system activities including brain neural activity and hematopoiesis.

The present study aims to use ¹⁸F-FDG PET/CT to assess the AmygA, and to investigate its association with CCTA assessed plaque morphological and inflammatory features as well as their ability in predicting future cardiovascular disease events.

Study Design

Study Type:
Observational
Anticipated Enrollment :
300 participants
Observational Model:
Cohort
Time Perspective:
Retrospective
Official Title:
Biological Interconnection of Brain Neurobiological Activity With Atherosclerotic Plaque Vulnerability and the Prognostic Value
Actual Study Start Date :
Jan 1, 2015
Anticipated Primary Completion Date :
Oct 30, 2022
Anticipated Study Completion Date :
Dec 30, 2022

Arms and Interventions

Arm Intervention/Treatment
CCTA imaging with 18F-FDG-PET/CT assessment

Group of patients with 18F-FDG-PET/CT imaging and Coronary Computed Tomographic Angiography within 90 days

Diagnostic Test: CCTA and 18F-FDG-PET/CT
18F-FDG-PET/CT imaging and comprehensive assessment of coronary plaque with CCTA within 90 days

Outcome Measures

Primary Outcome Measures

  1. Correlation Between amygdalar activity (neurobiological activity) and bone marrow hematopoiesis (hematopoietic activity) [at the index imaging]

    Amygdalar target-to-background ratio (TBR) = Amygdalar standardized uptake value (SUV) / Temporal lobe SUV Bone marrow TBR = Bone marrow SUV / Jugular vein SUV Correlation between amygdalar activity (neurobiological activity) and bone marrow hematopoiesis (hematopoietic activity) will be assessed

  2. Correlation Between amygdalar activity (neurobiological activity) and high-risk plaque [at the index imaging]

    High-risk plaque features will be assessed by CCTA including positive remodeling (PR, defined as lesion diameter/reference diameter ≥1.1), low attenuation plaque (LAP, defined as a focal central area of plaque with an attenuation density of <30 Hounsfield Units), spotty calcification (SC, defined as focal calcification within the coronary artery wall <3mm in maximum diameter), and the "napkin ring" sign (defined as a central area of low attenuation plaque that had a peripheral rim of high attenuation). Correlation Between amygdalar activity and number of high-risk plaque features will be assessed.

  3. Correlation Between amygdalar activity (neurobiological activity) and coronary inflammation [at the index imaging]

    Coronary inflammation will be assessed by FAI. Correlation Between amygdalar activity and FAI will be assessed

  4. Major adverse cardiac events [5 years after index imaging]

    Death from coronary heart disease, nonfatal myocardial infarction or hospitalization for unstable angina.

Secondary Outcome Measures

  1. Cardiovascular death, or nonfatal myocardial infarction [5 years after index imaging]

    Cardiovascular death, or nonfatal myocardial infarction

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
    1. Age: greater than 20
    1. Patients either absence of prior cancer or remission from cancer for at least 1 year prior to imaging and throughout the follow-up period;
    1. Patients absence of acute or chronic inflammatory or autoimmune disease at the time of imaging;
    1. Patients with CCTA performed within 90 days of 18F-FDG PET/CT scan as part of routine clinical practice
    1. Patients with diameter stenosis >30% by CCTA but without coronary revascularization
Exclusion Criteria:
    1. Complex coronary lesion (ostial lesion, unprotected left main lesion, chronic total occlusion, grafted vessels, etc)
    1. Coronary lesion with heavy calcification
    1. Chronic renal insufficiency (Serum creatinine >2.0mg/dL)
    1. Severe liver dysfunction (aspartate transaminase or alanine transferase > 5 times of upper normal limit)
    1. Pregnancy or potential pregnancy
    1. Life expectancy less than 5 year

Contacts and Locations

Locations

Site City State Country Postal Code
1 Fuwai Hospital Beijing China 200000
2 Shanghai Zhongshan Hospital Shanghai China 200032
3 Shanghai Tenth People's Hospital Shanghai China
4 Universal Medical Imaging Diagnostic Shanghai China

Sponsors and Collaborators

  • Shanghai Zhongshan Hospital

Investigators

  • Study Chair: Junbo Ge, Professor, Fudan University

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Shanghai Zhongshan Hospital
ClinicalTrials.gov Identifier:
NCT05545618
Other Study ID Numbers:
  • ZS-2022-9-15
First Posted:
Sep 19, 2022
Last Update Posted:
Sep 19, 2022
Last Verified:
Sep 1, 2022
Individual Participant Data (IPD) Sharing Statement:
Undecided
Plan to Share IPD:
Undecided
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Sep 19, 2022